Teladoc (TDOC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Stan Berenshteyn from Wells Fargo maintained a Hold rating on the stock and has a $10.00 price target.
Stan Berenshteyn has given his Hold rating due to a combination of factors affecting Teladoc’s current and future performance. The company’s guidance for 2025 has fallen short of market expectations, potentially leading to short-term pressure on the stock. The outlook for BetterHelp, a segment of Teladoc, indicates ongoing challenges with growth and margins, despite strategic adjustments.
Additionally, while there is some positive momentum in employer bookings, overall bookings have been under pressure, particularly in the health plan channel. The acquisition of Catapult is seen as a potential growth driver for chronic care, but its actual impact remains uncertain. These mixed signals, coupled with a cautious revenue and EBITDA outlook for 2025, contribute to the Hold rating, as the company navigates through these challenges.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TDOC in relation to earlier this year.